Aura Biosciences is a clinical-stage biotechnology company developing precision therapies for solid tumors, with a primary focus on ocular and urologic oncology. The company’s lead candidate, belzupacap sarotalocan (bel-sar), is a virus-like drug conjugate (VDC) designed to treat early choroidal melanoma while preserving vision. Bel-sar is currently in a global Phase 3 trial for first-line treatment of small choroidal melanoma and indeterminate lesions, and is in earlier clinical development for metastases to the choroid, cancers of the ocular surface, and non-muscle-invasive bladder cancer. The VDC technology utilizes modified human papilloma virus capsid proteins conjugated to light-activated cytotoxic molecules to target tumor cells via heparan sulfate proteoglycans. This mechanism induces acute necrosis and an adaptive immune response with minimal damage to surrounding healthy tissue. The company serves patients with rare and life-threatening ocular cancers and bladder cancer, addressing unmet medical needs where current standard of care options often result in significant vision loss or high recurrence rates.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage aurabiosciences.com
Sector Healthcare IR page ir.aurabiosciences.com
Tags
ocular oncology, urologic oncology, choroidal melanoma, bladder cancer, virus-like drug conjugates, precision medicine, solid tumors, clinical-stage, belzupacap sarotalocan, bel-sar, CoMpass trial
Press page —

Metrics

Valuation  
Market cap $ 732.853M
Market cap (USD) $ 732.853M
P/E -4.38
PEG —
P/BV 2.55
P/S —
P/OCF -6.70
P/FCF -6.68
Dividend yield —
Turnover / mcap —
Returns  
ROE -73.5%
ROI -116.0%
ROIC -92.4%
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 4
Quality score -76.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Assets 169.43M 182.503M 255.075M 223.935M 160.03M —
Net profit -106.191M -86.919M -76.408M -58.763M -35.251M 0
Free cash flow -85.189M -81.058M -64.556M -55.695M -34.535M —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Share price 5.45 8.22 8.86 10.5 16.98 —
Price performance 12m -0.34 -0.07 -0.16 -0.38 — —

Filed figures

Figure Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Lease liabilities (USD) — 975,000 20.9M 19.6M 18.8M 17.4M
Cash and deposits (USD) 17.4M 149M 122M 41.1M 31.7M 59.5M
Right-of-use assets (USD) — 950,000 20.7M 18.9M 17.4M 15.8M
Cash flow detail
Operating cash flow (USD) -24.3M -32.4M -54.6M -63.8M -79.8M -84.7M
Purchases of property, plant and equipment (USD) -771,000 -2.13M -1.09M -709,000 -1.25M -447,000
Change in payables (cash effect) (USD) -1.72M 1.05M 340,000 -1.04M 482,000 -846,000
Income taxes paid (cash effect) (USD) — — — — -100,000 -100,000
Share-based compensation (USD) 736,000 2.31M 6.41M 8.77M 11.7M 14.3M
Free cash flow (OCF - PPE - intangibles) (USD) -25.1M -34.5M -55.7M -64.6M -81.1M -85.2M
Income detail
Research and development expense (USD) 18M 25.2M 42.2M 65.2M 73.3M 90.3M
↳ 5y CAGR +38.0%
Total comprehensive income (USD) — -35.3M -58.8M -75.8M -87.2M -107M
Comprehensive income to owners (USD) — -35.3M -58.8M -75.8M -87.2M -107M
Reported Mar 23, 2022 Mar 15, 2023 Mar 15, 2023 Mar 27, 2024 Mar 30, 2026 Mar 30, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits

Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar

Early choroidal melanoma investor and analyst virtual event planned for December 8, 2026

Expected cash runway into 1H 2029

BOSTON, MA – November 9, 2026 – Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”) a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.

“During the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.

November 3, 2026

PDF Version

BOSTON, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference:

  • Stifel 2026 Healthcare Conference on Tuesday, November 10, 2026.

  • Fireside chat at 2:40 p.m. ET

The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class front-line vision-preserving therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of Bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.

September 2, 2026

PDF Version

BOSTON, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that Natalie Holles, CEO and President, will participate in the following upcoming investor conference:

  • **Morgan Stanley 24th Annual Global Healthcare Conference on Wednesday, September 16, 2026.**Fireside Chat at 2:35 p.m. ET

The live webcast of the fireside chat will be available on the “Investors & Media” page under the “Events & Presentations” section of the Company’s website at https://ir.aurabiosciences.com/events-and-presentations, where a replay of the webcast will be archived for 90 days following the presentation date.

About Aura Biosciences

Aura Biosciences is a clinical-stage biotechnology company developing bel-sar, a potentially transformative, first-in-class therapy for patients living with ocular cancers. Bel-sar represents an entirely novel approach to treating ocular cancers via its dual mechanisms of action of acute tumor necrosis and secondary anti-tumor immune activation. The Phase 3 registration study of bel-sar in early choroidal melanoma, the largest patient segment of uveal melanoma, is fully enrolled, and earlier stage studies in metastases to the choroid and cancers of the ocular surface are ongoing. Aura's mission is to improve outcomes for patients living with ocular cancers by delivering a therapy that not only arrests tumor growth but also preserves vision and quality of life.

Prompts

Aura Biosciences, Inc. (ticker AURA), listed in United States.

ETFs Holding Aura Biosciences, Inc.

ETF Weight in ETF Shares Market value As of
EVNT 0.49% 9,000 $ 64.62K Aug 31, 2026
WCEO 0.17% 2,404 $ 16.852K Jul 31, 2026
FSEV 0.06% 550 $ 3,905.00 Jun 30, 2026
FSEG 0.05% 388 $ 2,754.80 Jun 30, 2026
FESM 0.02% 196,067 $ 1.392M Jun 30, 2026
AVSC 0.01% 64,754 $ 467.524K Nov 16, 2026
DFAS 0.01% 327,663 $ 2.33M Nov 12, 2026
FEAC 0.00% 50 $ 355.00 Jun 30, 2026
DXUV 0.00% 9,233 $ 65.647K Nov 12, 2026
DCOR 0.00% 54,223 $ 385.526K Nov 12, 2026
DFUS 0.00% 23,384 $ 166.26K Nov 12, 2026
DFAC 0.00% 67,011 $ 476.448K Nov 12, 2026
DFAU 0.00% 8,911 $ 63.357K Nov 12, 2026